프로테이나제 K 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Proteinase K Market size was worth around USD 1.3 billion in 2023 and is estimated to grow at 7.5% CAGR from 2024 to 2032. The increasing prevalence of chronic and infectious diseases, along with advancements in biotechnology, is driving market growth. Chronic and infectious diseases are major drivers, as proteinase K plays a critical role in molecular diagnostics and research related to these conditions. Contributing factors to the rise in chronic diseases include an aging population, sedentary lifestyles, and poor dietary habits, leading to conditions such as cardiovascular diseases, diabetes, and cancer. Meanwhile, the spread of infectious diseases is driven by urbanization, global travel, and the rise of antimicrobial resistance.

Based on form, the powder segment dominated the market and accounted for USD 735.7 million in 2023. Powdered proteinase K is more stable than its liquid counterpart, offering a longer shelf life and easier storage conditions. This stability is essential for laboratory applications where enzymes must retain activity over extended periods without refrigeration. Additionally, powdered formulations typically have lower production and shipping costs, making them more economical for laboratories, especially those involved in large-scale applications. Based on therapeutic areas, the proteinase K market is segmented into infectious diseases, oncology, diabetes, cardiology, and other therapeutic areas.

The infectious diseases segment is anticipated to reach USD 795.3 million by 2032. The increasing prevalence of infectious diseases worldwide drives the demand for rapid and accurate diagnostic tests. Proteinase K plays an essential role in the isolation and purification of nucleic acids from pathogens, which is crucial for molecular diagnostics. This significantly bolsters the demand for diagnostic tools that utilize proteinase K. U.S. dominated the North American proteinase K market with the largest revenue of USD 456.2 million in 2023. The U.S. hosts numerous academic and research institutions engaged in genetic and cellular research, leading to high consumption of proteinase K.This indicates that the growth in federal funding for scientific research supports a continuous need for molecular biology tools, including enzymes. Additionally, the ongoing challenges posed by infectious diseases have heightened the need for rapid testing and research capabilities that utilize proteinase K, thereby driving the demand for enzymes involved in nucleic acid extraction.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic and infectious diseases
    • 3.2.1.2 Advancements in biotechnology
    • 3.2.1.3 Technological progress
    • 3.2.1.4 Government investment in research
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of enzymes
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Form, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Powder
• 5.3 Liquid

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Infectious diseases
• 6.3 Oncology
• 6.4 Diabetes
• 6.5 Cardiology
• 6.6 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Isolation and purification of genomic DNA & RNA
• 7.3 In situ hybridization
• 7.4 Mitochondria isolation
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Biotechnology companies
• 8.3 Contract research organizations
• 8.4 Diagnostic laboratories
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abcam
• 10.2 Agilent Technologies
• 10.3 Bioline (Meridian Biosciences)
• 10.4 BIORON
• 10.5 F. Hoffmann-La Roche
• 10.6 Merck
• 10.7 Minerva Biolabs
• 10.8 MP BIOMEDICALS.
• 10.9 New England Biolabs
• 10.10 Norgen Biotek
• 10.11 Promega Corporation
• 10.12 QIAGEN
• 10.13 Sisco Research Laboratories
• 10.14 Takara Bio
• 10.15 Thermo Fisher Scientific